



## PARKINSON'S DISEASE NEWS

<http://www.viartis.net/parkinsons.disease/news.htm>

20th May 2014 - New research

### PRAMIPEXOLE CLINICAL TRIAL RESULTS IN PARKINSON'S DISEASE

European Journal of Neurology [2014] 21 (5) : 736-743 (R.A.Hauser, A.H.Schapira, P. Barone, Y.Mizuno, O.Rascol, M.Busse, C.Debieuvre, M.Fraessdorf, W.Poewe)

Complete abstract : <http://www.ncbi.nlm.nih.gov/pubmed/24834511>

The long term safety and efficacy of pramipexole was assessed as an extended-release oral formulation and immediate release formulation in early or advanced Parkinson's Disease. Pramipexole, which is marketed as Mirapex, Mirapexin, and Sifrol, is a dopamine agonist. For more information go to Pramipexole : <http://www.rxlist.com/mirapex-drug.htm>



In those people with early Parkinson's Disease the reported side effects were somnolence (15%), peripheral edema (11%) and back pain (10%). The scores on the Parkinson's Disease symptom score (UPDRS) after over 2 years were down by 6.6 when using extended release pramipexole and 6.3 when using immediate release pramipexole. In those people with advanced Parkinson's Disease the reported side effects were dyskinesia (27%), somnolence (13%), and impulse control disorders (1%). The scores on the Parkinson's Disease symptom score (UPDRS) after over 2 years were down by 11.5 when using extended release pramipexole and 9.1 when using immediate release pramipexole.

In both early and advanced Parkinson's Disease better efficacy was achieved when using the extended release version of pramipexole. The adverse events were typical for dopaminergic drugs.

<http://www.viartis.net/parkinsons.disease/news/140520.pdf>

[mail@viartis.net](mailto:mail@viartis.net)

©2014 Viartis